metsera initial public offering

Metsera, IPO

Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care first-time share sales since October.

Investing.com on MSN · 3d

Metsera IPO opens 42% higher

Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its common stock to the public at $18.00 per share, the company's shares opened for trading at a higher price of $25.

Reuters · 3d

Weight-loss drug developer Metsera raises $275 million in US IPO

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company said on Thursday.

Bloomberg L.P. · 7d

Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to make their debuts as public companies.

Metsera Announces Pricing of Initial Public Offering

A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...

3don MSN

Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Nasdaq3d

Metsera, Inc. Prices Initial Public Offering at $18.00 per Share, Aiming for $275 Million Gross Proceeds

Metsera, Inc., a clinical-stage biotechnology company specializing in obesity treatments through injectable and oral hormone analog peptides, announced the pricing of its initial public ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Metsera, IPO

Trending now